Guidelines on preventing cardiovascular disease in clinical practice.
about
Absolute cardiovascular disease risk and shared decision making in primary care: a randomized controlled trialModifiable risk factors predicting major depressive disorder at four year follow-up: a decision tree approach.Barriers to apply cardiovascular prediction rules in primary care: a postal survey.National service framework's financial implications are huge.The Framingham Heart Study's impact on global risk assessmentThe design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study.Patients' preferences for ways to communicate benefits of cardiovascular medication.A multifaceted quality improvement intervention for CVD risk management in Australian primary healthcare: a protocol for a process evaluationThe accuracy of the Framingham risk-score in different socioeconomic groups: a prospective studyManagement of High Blood Pressure in Those without Overt Cardiovascular Disease Utilising Absolute Risk Scores.Lipoprotein(a): an emerging cardiovascular risk factor.Comparative accuracy of cardiovascular risk prediction methods in primary care patientsAbout time: diagnostic guidelines that help clinicians.Agreement between Framingham Risk Score and United Kingdom Prospective Diabetes Study Risk Engine in Identifying High Coronary Heart Disease Risk in North Indian Population.Predicting 10-Year Risk of Fatal Cardiovascular Disease in Germany: An Update Based on the SCORE-Deutschland Risk Charts.Paying for statins.Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study.Prevalence of Pragmatically Defined High CV Risk and its Correlates in LMIC: A Report From 10 LMIC Areas in Africa, Asia, and South America.First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.Cardiovascular Disease Risk Assessment: Insights from Framingham.Predictors and patterns of problematic Internet game use using a decision tree model.Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry.Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis.Statins: underused by those who would benefitChanging from CHD to CVD risk-based guidelines for the management of mild uncomplicated hypertension in different ethnic groups: implications for primary care.Impact of Sustained Use of a Multifaceted Computerized Quality Improvement Intervention for Cardiovascular Disease Management in Australian Primary Health Care.A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998.Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?Predicting melanoma risk: theory, practice and future challenges
P2860
Q24655103-89B62912-93D0-439A-BABC-877888E1B71FQ30907687-CE1FD992-96F7-4107-AD0F-31C9BC726190Q33268087-AEFF421E-15F0-4B56-85B8-FB2E9B9D6382Q33801993-362E8F47-AAE2-4D99-BABA-948DEEC28E85Q33996738-B28AFF01-4EB6-4E9D-8960-6E7DE95093BDQ34145516-F1EDC08B-DC5E-4D38-92F5-57A7383EE862Q34360730-DE7CD0B4-419E-4E0D-B1CB-81A4C386B87EQ34669129-ACE2D3E0-6E8B-4223-BCDF-611252DD0F55Q34788667-287F1568-55A6-4CFC-97EC-71BA6299F558Q35040566-B4FED82C-4B38-41A8-AA3E-97E89F86C5D2Q35072398-A4E480B4-B834-4E73-A864-60A8B69DC892Q35081894-09FF3310-5C97-4502-93EC-934B74E08E74Q35377637-26653FA0-0672-427D-8B81-98B02069FF2BQ35526063-946B2DC1-418C-412D-8010-9B9B8DEA26AEQ35976480-DAB97C0B-663B-4C6A-AA4C-BE6EAAB67BC3Q36128563-81DD2FC1-ECCC-436D-AAED-EF7CDD66A33DQ36147834-3668473E-B7B7-455C-8E51-7174F6463F50Q36716944-FAC8F651-4A6B-4B86-BB82-2F519DECABD2Q36832485-A0338C9E-7DC5-42F9-93D8-CF958FC4B0EFQ36862389-18AA01D2-066E-4BD4-9689-4B74C4D8DFE4Q36905510-10919BDE-47B8-490C-9114-6EA99851DBAFQ37604902-36A61804-D17C-4C50-9B27-D55BBEFD79A3Q37639937-5ABA3E79-5157-4760-8C21-340CBC09749BQ39020908-62DF593D-7B08-436D-A8CA-50DB585E6E23Q42768879-D3946CFC-A62B-412F-AA43-4C332D5C05D5Q45157924-795F457F-5107-436C-9275-F495B8E07F97Q47108577-E4E19436-E85C-4855-82CE-6015611D4318Q52936363-E45C36E2-3F59-475D-851F-58AB546D9B74Q55496270-2D8F1BE1-1B9D-4DD9-BFC1-2E06D459D8E0Q57742458-870AA594-58D3-4AEF-A92C-97EDE41EF8D7
P2860
Guidelines on preventing cardiovascular disease in clinical practice.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Guidelines on preventing cardiovascular disease in clinical practice.
@en
Guidelines on preventing cardiovascular disease in clinical practice.
@nl
type
label
Guidelines on preventing cardiovascular disease in clinical practice.
@en
Guidelines on preventing cardiovascular disease in clinical practice.
@nl
prefLabel
Guidelines on preventing cardiovascular disease in clinical practice.
@en
Guidelines on preventing cardiovascular disease in clinical practice.
@nl
P2860
P356
P1433
P1476
Guidelines on preventing cardiovascular disease in clinical practice.
@en
P2093
P2860
P304
P356
10.1136/BMJ.320.7236.659
P407
P577
2000-03-01T00:00:00Z